Immunic Inc. (IMUX)
NASDAQ: IMUXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMUX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $111.01M
- EPS (TTM)
- -$3.53
- Dividend yield
- None
- 52-week range
- 5.06 – 17.43
- Day range
- 6.97 – 7.56
- Volume / Avg
- 295.91K / 343.44K
- Beta
- —
- Shares outstanding
- 15.88M
52-week range
IMUX stock today
Immunic (IMUX) closed at $6.99 on Nov 20, down 5.41% (-$0.40), versus the S&P 500's 3.70% decline. Shares are 59.9% below their 52-week high of $17.43, set on Aug 19, 2026 and 38.1% above the 52-week low of $5.06, near the bottom of the past year's range. IMUX is up 30.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.9%.
Immunic has posted a net loss over the last twelve months (EPS of -$3.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Immunic
Company profileImmunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erik Lundgren
- Headquarters
- New York, NY
- Employees
- 100
- IPO year
- 2014
- Website
- imux.com
Financial highlights
Full financialsImmunic reported a net loss of $97.2 million, compared with a loss of $100.5 million a year earlier. Diluted earnings per share came in at -$0.62.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-97.17M | $-100.51M | $-93.61M | $-120.41M | $-92.94M |
| EPS (diluted) | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$42.55+508.73%
- Strong buy 0
- Buy 13
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 13, 2026
- EPS actual vs est.
- $-0.99 vs $-0.82
- Surprise
- -20.73%
IMUX news
All IMUX news- Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026NasdaqIMUX, BRK.A
- Immunic, Inc. Hosts Progressive Multiple Sclerosis Research and Development Day Webinar on November 5, 2026Nasdaq
- Immunic to Participate in Investor Conferences in NovemberPR Newswire
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026PR Newswire
- New Strong Buy Stocks for October 22ndNasdaqSTX, TGS, BBCP, IMUX
- Immunic Names Jaa Roberson Chief People OfficerNasdaq
- Immunic Appoints Jaa Roberson as Chief People OfficerPR Newswire
Immunic peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OKUROnKure Therapeutics Inc. Class A | 2.70 | -2.17% | $111.21M | vs IMUX |
| MENSJyong Biotech Ltd. | 1.45 | -17.14% | $110.24M | vs IMUX |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs IMUX |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs IMUX |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs IMUX |
| ADAGAdagene Inc. ADR | 1.76 | -12.44% | $118.17M | vs IMUX |
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs IMUX |
| FHTXFoghorn Therapeutics Inc. | 1.72 | -3.37% | $103.14M | vs IMUX |
Indexes, lists and sector
Immunic stock FAQ
What is Immunic's stock price today?
IMUX last traded at $6.99 as of Nov 20, 4:00 PM EST, down 5.41% on the day. Prices are delayed at least 15 minutes.
Does Immunic pay a dividend?
No. Immunic does not currently pay a regular cash dividend.
Who is Immunic's CEO?
Mr. Erik Lundgren is the chief executive officer of Immunic Inc., which has about 100 employees.
Has IMUX ever split its stock?
Yes. The most recent IMUX stock split was a 1-for-10 split on Apr 27, 2026, one of 2 splits on record.
What is the IMUX 52-week high?
The 52-week high for IMUX is $17.43 and the 52-week low is $5.06. The stock is currently 59.9% below its high.